A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients With Parkinson's Disease.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients With Parkinson's Disease.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs CEP 1347 (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms PRECEPT
  • Sponsors Cephalon
  • Most Recent Events

    • 08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 08 Jun 2017 Results of longitudinal analysis of PRECEPT and PPMI trials to estimate the degree of enrichment and impact of reduced dopamine transporter (DAT) binding as a biomarker on future trials, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 03 May 2012 Company (Teva Pharmaceutical Industries) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top